(MENAFN- America News Hour) According
to the current analysis of Reports and Data, the global Preimplantation
genetic testing market was valued at USD 347.7 million in 2018 and is expected to
reach USD 762.6 million by the year 2026, at a CAGR of 10.1%. Preimplantation
Genetic testing identifies genetic defects in embryos, which are developed
through Vitro Fertilization (IVF) before pregnancy. Preimplantation genetic
diagnosis (PGD) is made when one or both the hereditary parents have a known
hereditary disorder, and testing is performed on the embryo to determine
whether it carries the same hereditary disorder. It is used is growing due
to; increasing number of cases related to the predominance of genetic,
hereditary and chromosomal diseases, rising knowledge amongst the population
about the avoidance of genetic disorders.
To Get Sample Copy of
Report visit: https://www.reportsanddata.com/sample-enquiry-form/2244
Companies considered and profiled in this market study Natera, Inc.; CooperSurgical, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.; IGENOMIX; and others
A growing number of people suffering from genetic diseases are expected to increase demand for preimplantation genetic testing procedures to have a healthy child. Due to high pregnancy chances with the preimplantation genetic testing procedure as compared to other fertility treatments, the demand for PGI testing is expected to witness high demand among people seeking IVF treatments. Increasing applications for preimplantation genetic testing for the diagnosis of diseases like cancer and other minor disabilities like deafness is expected to create high growth opportunities for preimplantation genetic testing market stakeholders. Stringent government regulations related to the use of PGD have hindered the market growth of PGD market.
Further key findings from the report suggest
- Availability of a significant number of
services related to early diagnosis of specific gene mutation in embryo
marked the dominant position of PGD in 2018
- Advancements in the detection of
chromosomal anomalies by executing non-invasive prenatal testing results
in a maximum share of this segment in 2018
- The market chromosomal abnormalities
segment is expected to reach USD 271.0 million by the year 2026, growing
at a CAGR of 6.8% during the forecast period
- Enlarging utilization rate of FISH probe
sets and benefits associated with the detection of a single-gene disorder
is anticipated to fuel the growth of X-linked diseases segment
- Preimplantation Genetic Screening (PGS)
seems to be a reasonable intervention to enhance the efficiency of
selecting chromosomally normal embryo during IVF cycles. It is
increasingly being applied for embryo screening due to ever-expanding IVF,
which is projected to create lucrative growth opportunities in the near
future
- Increasing use Of PGT in embryo HLA
typing for stem cell therapy is expected to boost segment growth. This
further proceeds to the advantages of PGS testing for the identification
of HLA compatible embryos during stem cell therapy
- Key participants are actively involved in
the expansion of the distribution network for their products as well as
R & D activities for the development of novel PGT services.
In October 2018, Illumina Inc. joined an agreement with Vitrolife AB
under which Vitrolife act as a distributor supplier of Illumina's PGT
products in EMEA and America.
- Asia Pacificmarket is observed to
showcase the fastest growing CAGR due to the rise in medical tourism and
rising development of IVF and PGD clinics in Asian countries.
- North America holds the largest revenue
share of 32.0% in 2018 due to an increased usage of PGD and PGS for the
delivery of genetically healthy offspring during IVF procedures.
Click here to avail the report at an unbelievable discount rate: https://www.reportsanddata.com/discount-enquiry-form/2244
For
this report, Reports and Data have segmented the Preimplantation genetic
testing market based on test type, type, application, end-use, and region:
Test Type (Revenue, USD Million; 2016–2026)
- Preimplantation Genetic Diagnosis (PGD)
- Preimplantation Genetic Screening (PGS)
Type (Revenue, USD Million; 2016–2026)
- Chromosomal Abnormalities
- X-linked Diseases
- Embryo Testing
- Aneuploidy Screening
- HLA Typing
- Other PGT Types
Application (Revenue, USD Million; 2016–2026)
- Embryo HLA Typing for Stem Cell Therapy
- IVF Prognosis
- Late Onset Genetic Disorders
- Inherited Genetic Disease
- Others
End Use (Revenue, USD Million; 2016–2026)
- Maternity Centers & Fertility Clinics
- Hospitals, Diagnostic Labs, and Service
Providers
- Research Laboratories & Academic
Institutes
Regional Outlook (Revenue in USD Million; 2016–2026)
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Connect with an expert for customization of Report @ https://www.reportsanddata.com/request-customization-form/2244
About
Reports and Data
Reports and Data is a market research
and consulting company that provides syndicated research reports, customized
research reports, and consulting services. Our solutions purely focus on your
purpose to locate, target and analyze consumer behavior shifts across
demographics and industries to help clients make smarter business decisions. We
offer market intelligence studies ensuring relevant and fact-based research
across multiple industries including Healthcare, Technology, Chemicals, Power,
and Energy. We consistently update our research offerings to ensure that our
clients are aware of the latest trends existent in the market. Reports and Data
has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John Watson
Head of Business Development
Direct Line: +1-212-710-1370
E-mail:
Reports and Data | Web: www.reportsanddata.com
ReportsandData
We are a boutique market intelligence and strategic consulting firm dedicated to having a meaningful impact on businesses across the globe. Our stellar estimation and forecasting models have earned recognition across majority of the business forum.
MENAFN21012020007010068ID1099582346
-MENAFN21012020007010068ID1099582346-->
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.